XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Note 13 - Capital Stock
9 Months Ended
Apr. 30, 2023
Notes to Financial Statements  
Equity [Text Block]

NOTE 13:

CAPITAL STOCK

 

Equity Financing

 

On May 17, 2021, we filed a Form S-3 shelf registration statement under the United States Securities Act of 1933, as amended (the “Securities Act”), which was declared effective by the SEC on June 1, 2021, providing for the public offer and sale of certain securities of the Company from time to time, at our discretion, of up to an aggregate offering amount of $200 million (the “2021 Shelf”), which included an at-the-market offering agreement prospectus (the “May 2021 ATM Offering”) covering the offering, issuance and sale of up to a maximum offering of $100 million as part of the $200 million under the 2021 Shelf.

 

 

On May 14, 2021, we entered into an at-the-market offering agreement (the “2021 ATM Offering Agreement”) with H.C. Wainwright & Co., LLC and certain co-managers (collectively, the “2021 ATM Managers”) as set forth in the 2021 ATM Offering Agreement under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100 million through the 2021 ATM Managers selected by us.

 

On November 26, 2021, we filed a prospectus supplement to our 2021 Shelf with respect to the continuation of the May 2021 ATM Offering Agreement with the 2021 ATM Managers under which we may, if eligible, from time to time, sell shares of our common stock having an aggregate offering price of up to an additional $100 million for a total of $200 million through the 2021 ATM Managers selected by us (the “November 2021 ATM Offering”; and, collectively with the May 2021 ATM Offering, the “2021 ATM Offering”).

 

On November 16, 2022, we filed a Form S-3 automatic shelf registration statement under the Securities Act, which became effective upon filing, providing for the public offer and sale of certain securities of the Company from time to time, at our discretion, of an undetermined dollar value of common stock, debt securities, warrants to purchase common stock or debt securities, subscription receipts for and units which include common stock, debt securities, warrants or any combination thereof (the “2022 Shelf”), which included an at-the-market offering agreement prospectus (the “2022 ATM Offering”; and, collectively, with the 2021 ATM Offering, the “ATM Offerings”) covering the offering, issuance and sale of up to a maximum offering of $300 million under the 2022 Shelf.

 

On November 16, 2022, we entered into an at-the-market offering agreement (the “2022 ATM Offering Agreement”) with H.C. Wainwright & Co., LLC and certain co-managers (collectively, the “2022 ATM Managers”) as set forth in the 2022 ATM Offering Agreement under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $300 million through the 2022 ATM Managers selected by us.

 

During the three and nine months ended April 30, 2023, we issued nil and 6,201,553 shares of the Company’s common stock under the 2021 ATM Offering for net cash proceeds of nil and $25,526, respectively.

 

During the three and nine months ended April 30, 2023, we issued 2,912,000 and 8,969,700 shares of the Company’s common stock under the 2022 ATM Offering for net cash proceeds of $10,599 and $32,893, respectively.

 

Share Purchase Warrants

 

A continuity schedule of our outstanding share purchase warrants for the three and nine months ended April 30, 2023, is as follows:

 

  

Number of
Warrants

  

Weighted Average
Exercise Price

 

Balance, July 31, 2022

  3,615,454  $1.92 

Issuance of Replacement Warrants (Note 3,13)

  4,660,580   2.84 

Exercised

  (3,410,898)  1.80 

Expired

  (27,550)  1.80 

Balance, October 31, 2022

  4,837,586   2.85 

Exercised

  (45,000)  1.46 

Balance, January 31, 2023

  4,792,586   2.93 

Balance, April 30, 2023

  4,792,586  $2.88 

 

 

A summary of our share purchase warrants outstanding and exercisable as of April 30, 2023, is as follows:

 

Weighted Average
Exercise Price

  

Number of

Warrants

Outstanding

  

Weighted Average

Remaining Contractual
Life (Years)

 

Expiry Date

$1.72   144,194   0.05 

May 20, 2023

 1.64   25,000   0.06 

May 21, 2023

 1.43   766,362   0.09 

June 2, 2023

 3.17   3,675,212   1.36 

September 7, 2024

 4.13   181,818   2.93 

April 5, 2026

$2.88   4,792,586   1.17  

 

As at April 30, 2023, 4,585,768 Replacement Warrants, which were issued in connection with UEX Acquisition and dominated in Canadian dollars, remained outstanding.

 

During the nine months ended April 30, 2023, we received cash proceeds totaling $6,206 from the exercise of share purchase warrants.

 

Subsequent to April 30, 2023, 928,188 warrants with expiry dates from May 20 to June 2, 2023 were exercised and proceeds of $1,060 were received.

 

Stock Options

 

As of April 30, 2023, we had one stock option plan, our 2022 Stock Incentive Plan (the “2022 Plan”), which superseded and replaced the Company’s 2021 Stock Incentive Plan (collectively the “Stock Incentive Plan”), such that no further shares are issuable the 2021 Stock Incentive Plan.

 

A continuity schedule of our outstanding stock options for the three and nine months ended April 30, 2023, is as follows:

 

  

Number of Stock
Options

  

Weighted Average
Exercise Price

 

Balance, July 31, 2022

  8,880,527  $1.58 

Issuance of Replacement Options (Note 3)

  2,301,750   1.90 

Granted

  5,000   4.23 

Exercised

  (2,331,222)  1.61 

Balance, October 31, 2022

  8,856,055   1.65 

Granted

  15,464   3.78 

Exercised

  (197,110)  2.10 

Balance, January 31, 2023

  8,674,409   1.65 

Granted

  100,000   3.22 

Exercised

  (337,500)  1.61 

Balance, April 30, 2023

  8,436,909  $1.67 

 

 

The table below sets forth the number of shares issued and cash received upon exercise of our stock options:

 

  

Three Months Ended April 30,

  

Nine Months Ended April 30,

 
  

2023

  

2022

  

2023

  

2022

 

Number of Options Exercised on Cash Basis

  -   404,832   138,537   807,580 

Number of Options Exercised on Forfeiture Basis

  337,500   777,773   2,727,295   1,650,402 

Total Number of Options Exercised

  337,500   1,182,605   2,865,832   2,457,982 

Number of Shares Issued on Cash Exercise

  -   404,832   138,537   807,580 

Number of Shares Issued on Forfeiture Basis

  204,693   595,478   1,565,059   1,140,065 

Total Number of Shares Issued Upon Exercise of Options

  204,693   1,000,310   1,703,596   1,947,645 

Cash Received from Exercise of Stock Options

 $-  $404  $206  $851 

Total Intrinsic Value of Options Exercised

 $858  $4,891  $6,834  $7,685 

 

A continuity schedule of our outstanding unvested stock options as of April 30, 2023, and the changes during the period, is as follows:

 

  

Number of Unvested
Stock Options

  

Weighted Average

Grant-Date Fair Value

 

Balance, July 31, 2022

  2,186,154  $1.79 

Issuance of Replacement Options (Note 3)

  2,301,750   1.75 

Granted

  5,000   2.70 

Vested

  (2,467,341)  1.79 

Balance, October 31, 2022

  2,025,563   1.74 

Granted

  15,464   2.40 

Vested

  (394,858)  1.78 

Balance, January 31, 2023

  1,646,169  $1.74 

Granted

  100,000   2.04 

Vested

  (15,680)  1.56 

Balance, April 30, 2023

  1,730,489  $1.76 

 

As at April 30, 2023, the aggregate intrinsic value of all of our outstanding stock options was estimated at $9,666 (vested: $8,903 and unvested: $763). As at April 30, 2023, our unrecognized compensation cost related to unvested stock options was $1,219, which is expected to be recognized over 0.89 years.

 

 

A summary of our stock options outstanding and exercisable as of April 30, 2023, is as follows:

 

 

 

Options Outstanding

  

Options Exercisable

 

Range of

Exercise
Prices

 

Outstanding at
April 30, 2023

  

Weighted
Average
Exercise Price

  

Weighted
Average
Remaining
Contractual
Term (Years)

  

Exercisable at
April 30, 2023

  

Weighted
Average
Exercise Price

  

Weighted
Average
Remaining
Contractual
Term (Years)

 

$0.80 to $0.99

  3,592,124  $0.92   6.78   3,592,124  $0.92   6.78 

$1.00 to $1.99

  2,442,500   1.29   4.12   2,000,832   1.33   3.44 

$2.00 to $2.99

  918,954   2.22   7.96   687,183   2.22   7.87 

$3.00 to $3.99

  1,478,331   3.76   8.37   425,031   3.78   7.61 

$4.00 to $4.23

  5,000   4.23   9.49   1,250   4.23   9.49 
   8,436,909  $1.67   6.42   6,706,420  $1.36   5.95 

 

Restricted Stock Units

A summary of our outstanding and unvested restricted stock units (“RSU”s) as of April 30, 2023, is as follows:

 

Grant Date

 

Number of
Restricted Stock
Units

  

Grant Date
Fair Value

  

Remaining Life
(Years)

  

Aggregate
Intrinsic Value

 

July 16, 2020

  217,498  $0.91   0.21  $568 

July 21, 2021

  271,746   2.15   1.23   709 

May 01, 2022

  58,824   4.25   2.01   154 

July 29, 2022

  287,966   3.98   2.25   752 
   836,034  $2.61   1.37  $2,183 

 

During the three and nine months ended April 30, 2023, our stock-based compensation related to RSUs were $283 and $869 (three and nine months ended April 30, 2022: $183 and $560), respectively. As at April 30, 2023, our unrecognized compensation costs related to unvested RSUs totaled $879, which is expected to be recognized over a period of approximately 1.40 years.

 

Performance Based Restricted Stock Units

 

During the three and nine months ended April 30, 2023, our stock-based compensation relating to amortization of target performance based restricted stock units (“PRSU”s) totaled $99 and $298 (three and nine months ended April 30, 2022: $73 and $220), respectively. As at April 30, 2023, our outstanding unvested PRSUs were 734,582 ( July 31, 2022: 734,582), and our unrecognized compensation costs relating to unvested PRSUs totaled $683 ( July 31, 2022: $981), which is expected to be recognized over a period of approximately 1.71 years.

 

 

Stock-Based Compensation

 

A summary of our stock-based compensation expense is as follows:

 

  

Three Months Ended

April 30,

  

Nine Months Ended

April 30,

 
  

2023

  

2022

  

2023

  

2022

 

Stock-Based Compensation for Consultants

                

Common stock issued to consultants

 $107  $158  $382  $664 

Amortization of stock option expenses

  95   37   467   174 
   202   195   849   838 

Stock-Based Compensation for Management

                

Amortization of stock option expenses

  95   91   323   382 

Amortization of RSU and PRSU expenses

  346   256   1,053   780 
   441   347   1,376   1,162 

Stock-Based Compensation for Employees

                

Common stock issued to employees

  188   282   675   894 

Amortization of stock option expenses

  314   127   1,441   632 

Amortization of RSU expenses

  37   -   114   - 
   539   409   2,230   1,526 
  $1,182  $951  $4,455  $3,526